Two Sigma Advisers
ATOS icon

Two Sigma Advisers’s Atossa Therapeutics ATOS Stock Holding History

Two Sigma Advisers’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,220
Closed -$10.8K – 199
2025
Q4 		$10.8K Buy
+1,220
New +$15.4K ﹤0.01% 2324
2025
Q3 		– Sell
-2,280
Closed -$28.4K – 2356
2025
Q2 		$28.4K Sell
2,280
-1,513
-40% -$18.1K ﹤0.01% 2284
2025
Q1 		$38.3K Buy
3,793
+966
+34% +$11.7K ﹤0.01% 2332
2024
Q4 		$40K Buy
2,827
+1,927
+214% +$37.6K ﹤0.01% 2298
2024
Q3 		$20.5K Sell
900
-2,713
-75% -$54.8K ﹤0.01% 2252
2024
Q2 		$64.5K Buy
3,613
+2,380
+193% +$52.7K ﹤0.01% 2347
2024
Q1 		$33.3K Sell
1,233
-447
-27% -$7.18K ﹤0.01% 2372
2023
Q4 		$22.2K Buy
1,680
+260
+18% +$2.81K ﹤0.01% 2444
2023
Q3 		$15.7K Sell
1,420
-407
-22% -$5.9K ﹤0.01% 2332
2023
Q2 		$34.5K Sell
1,827
-2,226
-55% -$27K ﹤0.01% 2296
2023
Q1 		$44.1K Sell
4,053
-2,054
-34% -$22.9K ﹤0.01% 2464
2022
Q4 		$48.4K Sell
6,107
-920
-13% -$10.6K ﹤0.01% 2367
2022
Q3 		$88K Sell
7,027
-1,460
-17% -$21.2K ﹤0.01% 2325
2022
Q2 		$139K Sell
8,487
-36,953
-81% -$582K ﹤0.01% 2346
2022
Q1 		$852K Sell
45,440
-61,089
-57% -$1.24M ﹤0.01% 1722
2021
Q4 		$2.56M Buy
106,529
+100,662
+1,716% +$3.68M 0.01% 1068
2021
Q3 		$287K Buy
5,867
+3,300
+129% +$192K ﹤0.01% 2132
2021
Q2 		$243K Sell
2,567
-660
-20% -$34.9K ﹤0.01% 2212
2021
Q1 		$102K Buy
3,227
+2,507
+348% +$91.6K ﹤0.01% 2440
2020
Q4 		$10K Sell
720
-93
-11% -$2.15K ﹤0.01% 2356
2020
Q3 		$30K Buy
+813
New +$39K ﹤0.01% 2349

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Advisers's ATOS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 1,220 shares — an estimated $10.8K sold.

Two Sigma Advisers first reported a position in ATOS in Q3 2020 and held it in 21 quarters. The position peaked at $2.56M in Q4 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • Two Sigma Advisers reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 1,220 Atossa Therapeutics shares in Q1 2026, an estimated $10.8K.
  • Two Sigma Advisers first reported a position in Atossa Therapeutics in Q3 2020 and held it in 21 quarters.
  • Two Sigma Advisers's Atossa Therapeutics position peaked at $2.56M in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.